Clinical bottom line
Chronic hypertension in pregnancy remains a significant contributor to maternal and fetal morbidity. Recent evidence emphasizes individualized blood pressure (BP) targets, risk stratification based on comorbidities, and close monitoring to optimize outcomes. Emerging data suggest that tighter BP control may reduce adverse neonatal events without increasing maternal risks, but management must balance fetal growth concerns and maternal safety. Integration of liver function tests and kidney disease status into risk assessment enhances prognostication. These advances warrant cautious incorporation into clinical practice, pending further validation.
What the evidence shows
Chronic hypertension complicates approximately 1–5% of pregnancies and is associated with increased risks of preeclampsia, fetal growth restriction, preterm birth, and maternal cardiovascular events (Booker et al., 2020). Lopes-Pereira et al. (2026) provide a comprehensive review highlighting the importance of risk stratification, recommending tailored management strategies that consider baseline maternal cardiovascular and renal status.
Recent prospective data from the Chronic Hypertension in Pregnancy Project and the Control of Hypertension in Pregnancy Study (Leeson et al., 2022) demonstrate that tighter BP control (targeting systolic BP <140 mmHg and diastolic BP <90 mmHg) is associated with improved fetal outcomes, including reduced rates of small-for-gestational-age neonates and neonatal intensive care admissions. This contrasts with prior concerns that aggressive BP lowering might impair uteroplacental perfusion.
Moore et al. (2024) further refine neonatal risk prediction by showing that mean arterial pressure correlates with neonatal outcomes in mild chronic hypertension, suggesting that continuous BP monitoring could guide therapy adjustments more effectively than isolated office measurements.
Comorbid chronic kidney disease (CKD) complicates management and worsens prognosis. Reynolds et al. (2020) and Fischer et al. (2007) underscore that CKD presence necessitates multidisciplinary care, as it increases risks for superimposed preeclampsia and adverse fetal outcomes. These studies advocate for early nephrology involvement and individualized BP targets.
Shah et al. (2024) identify liver function tests as prognostic biomarkers in hypertensive disorders of pregnancy, including chronic hypertension, where abnormal liver enzymes correlate with increased maternal and fetal complications. This suggests a potential role for routine hepatic monitoring in high-risk pregnancies.
Caveats and uncertainty
Despite encouraging findings, several uncertainties remain. Most studies are observational or derived from heterogeneous cohorts, limiting generalizability. The optimal BP target remains debated, especially in women with severe hypertension or significant comorbidities. Leeson et al. (2022) caution that aggressive BP lowering may not be suitable for all, and individualized assessment is essential.
The impact of antihypertensive medication choice on fetal neurodevelopment and teratogenicity is incompletely understood, with limited data in pregnancy-specific populations (Pack et al., 2024). Safety profiles of newer agents require further study.
Integration of liver function tests into routine risk stratification is promising but not yet standardized, and thresholds for intervention remain undefined (Shah et al., 2024).
Finally, long-term maternal cardiovascular outcomes post-pregnancy hypertension require ongoing surveillance, as chronic hypertension in pregnancy portends future cardiovascular disease risk (Lopes-Pereira et al., 2026).
How this may change practice
Clinicians should consider adopting individualized BP targets informed by recent evidence favoring tighter control in select patients with chronic hypertension, balancing maternal and fetal risks. Incorporating mean arterial pressure monitoring may refine treatment adjustments.
Early identification of comorbid CKD and multidisciplinary management are critical to optimize outcomes. Routine assessment of liver function tests in hypertensive pregnancies could enhance risk stratification, though practice guidelines have yet to incorporate this fully.
Patient counseling should emphasize the importance of close monitoring and potential medication adjustments, with awareness of current gaps in safety data for some antihypertensives.
These advances underscore the need for updated clinical protocols and prospective trials to validate optimal management strategies for chronic hypertension in pregnancy.